Evidence map›Paper›PMID 23911753›Full record

ArticleNeurology2013

Antihypertensive medication use and risk of cognitive impairment: the Honolulu-Asia Aging Study.

Rebecca P Gelber, G Webster Ross, Helen Petrovitch, Kamal H Masaki, Lenore J Launer, Lon R White

Abstract read
In one paragraph

Article in Neurology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Hypertension and cognitive dysfunction: a narrative review.Journal of Yeungnam medical science · 2023
    Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Rebecca P GelberVA Pacific Islands Health Care System, University of Hawaii John A. Burns School of Medicine, Honolulu, HI, USA. rebecca.gelber@va.gov
G Webster Ross
Helen Petrovitch
Kamal H Masaki
Lenore J Launer
Lon R White

Funding

Epidemiology of Brain Aging in the Very OldU01AG019349 · NIA · KUAKINI MEDICAL CENTER · PI WHITE, LON RAY · 2001 to 2011
$14.0M
FOXO3 Genotype, InflammAging, Cardiovascular Disease, and Dementia. Kuakini Hawaii Lifespan Study III. Administrative Supplement.R01AG027060 · NIA · KUAKINI MEDICAL CENTER · PI Gregory J. Tranah, BRADLEY JOHN WILLCOX · 2005 to 2026
$8.1M
Epidemiology of Aging and Dementia-Autopsy ResearchU01AG017155 · NIA · KUAKINI MEDICAL CENTER · PI WHITE, LON RAY · 2008 to 2010
$4.1M
Brain aging and cardiovascular risk factors and diseaseZIAAG007480 · NIA · NATIONAL INSTITUTE ON AGING · PI LAUNER, LENORE J · 2011 to 2025
$2.7M
HONOLULU ASIA AGING STUDYN01AG042149 · NIA · KUAKINI MEDICAL CENTER · PI FOLEY, DANIEL · 1994 to 2000
$1.1M
HONOLULU HEART PROGRAMN01HC005102 · HC · KUAKINI MEDICAL CENTER · PI CURB, JESS DAVID · 1990 to 1997
–
NHLBI NIH HHS N01 HC005102NIA NIH HHS N01 AG042149NIA NIH HHS N01-AG-4-2149NIA NIH HHS R01 AG027060NIA NIH HHS U01 AG017155NIA NIH HHS U01 AG019349
6 · The paper itself

Abstract

objectiveTo determine the associations between classes of antihypertensive medication use and the risk of cognitive impairment among elderly hypertensive men.

methodsThe Honolulu-Asia Aging Study is a prospective, community-based cohort study of Japanese American men conducted in Honolulu, Hawaii. We examined 2,197 participants (mean age 77 years at cohort entry, 1991-1993, followed through September 2010) with hypertension and without dementia or cognitive impairment at baseline, who provided information on medication use. Cognitive function was assessed at 7 standardized examinations using the Cognitive Abilities Screening Instrument (CASI). Cognitive impairment was defined as a CASI score <74.

resultsA total of 854 men developed cognitive impairment (median follow-up, 5.8 years). β-Blocker use as the sole antihypertensive drug at baseline was consistently associated with a lower risk of cognitive impairment (incidence rate ratio [IRR] 0.69; 95% confidence interval [CI] 0.50-0.94), as compared with men not taking any antihypertensive medications, adjusting for multiple potential confounders. The use of diuretics, calcium channel blockers, angiotensin-converting enzyme inhibitors, or vasodilators alone was not significantly associated with cognitive impairment. Results were similar excluding those with cardiovascular disease or <1 year of follow-up, and additionally adjusting for pulse pressure, heart rate, baseline and midlife systolic blood pressure, and midlife antihypertensive treatment (IRR 0.65; 95% CI 0.45-0.94). The association between β-blocker use and cognitive impairment was stronger among men with diabetes, men aged >75 years, and those with pulse pressure ≥70 mm Hg.

conclusionsβ-blocker use is associated with a lower risk of developing cognitive impairment in elderly Japanese American men.

Indexed as

Adrenergic beta-AntagonistsAgedAged, 80 and overAgingAntihypertensive AgentsAsiaAsianCognition DisordersCohort StudiesFollow-Up StudiesHawaiiHumansHypertensionMaleProspective StudiesRisk FactorsAdrenergic beta-AntagonistsAntihypertensive Agents

Identifiers

PMID23911753
PMCPMC3885214

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.